S41 - Neuro-oncology

Event Time: Thursday April 27, 2017 1:00 pm to 3:00 pm
Topic(s): Neuro-oncology
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:24 PM 003 Clinical and molecular characteristics of glioneuronal tumors Julie Miller, MD
Disclosure:
Dr. Miller has nothing to disclose.

1:36 PM 004 Tumor stem cell RNA-loaded dendritic cell vaccine for recurrent glioblastoma: a phase 1 trial Anastasie Dunn-Pirio, MD
Disclosure:
Dr. Dunn-Pirio has nothing to disclose.

1:48 PM 005 Targeting carcinoma–astrocyte gap junctions in brain metastasis Adrienne Boire, MD
Disclosure:
Dr. Boire has nothing to disclose.

2:00 PM 006 Identification of clinically actionable PI3K pathway mutations in brain metastases from breast cancer Ugonma Chukwueke, MD
Disclosure:
Dr. Chukwueke has nothing to disclose.

2:12 PM 007 Microtubule Associated Protein (MAP) 1B: Antigen of PCA-2 IgG, Biomarker of Small-Cell Lung Carcinoma-related Paraneoplastic Neurological Autoimmunity Avi Gadoth
Disclosure:
,,,Mayo Foundation has applied for a patent relating to commercial testing for MAP1B autoantibody that is the subject of this report.,,,

Dr. Gadot has received royalty payments from Mayo Foundation.

2:24 PM 008 Germline genetic mutations contribute to the development of primary brain tumors: a review of a multigene panel testing cohort Amanda Bergner
Disclosure:
Dr. Bergner has received personal compensation for activities with Ambry Genetics as an employee. Dr. Bergner has received royalty payments from UpToDate.

Register Now

Related Courses